Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 17/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698838 | 0.93 | HCRTR1 (0.42) | HCRTR1HCRTR2CNR2CNR1 | |
| SCHEMBL21397907 | 0.92 | POLB (0.44) | HCRTR1HCRTR2CNR2 | |
| SCHEMBL21397910 | 0.92 | POLB (0.40) | HCRTR1HCRTR2CNR2 | |
| SCHEMBL10146061 | 0.90 | POLB (0.46) | HCRTR1HCRTR2CNR2 | |
| SCHEMBL12069368 | 0.87 | USP7 (0.47) | HCRTR1HCRTR2CNR2 | |
| SCHEMBL31061842 | 0.84 | HCRTR1 (0.37) | HCRTR1HCRTR2CNR2 | |
| SCHEMBL22930727 | 0.81 | POLB (0.37) | HCRTR1HCRTR2CNR2 | |
| SCHEMBL13188862 | 0.81 | HCRTR1 (0.40) | HCRTR1HCRTR2CNR2 | |
| SCHEMBL13189197 | 0.81 | PLAT (0.40) | HCRTR1HCRTR2CNR2 | |
| Hydrochloric Acid SCHEMBL3802377 | 0.79 | PLAT (0.39) | HCRTR1HCRTR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-20230193231-A1 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230193231-A1 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-11358956-B2 | Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2022-06-14 | — | — | US | disclosed |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9296736-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8569341-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037032-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP4K2B, PHKG1 | HCRTR1 4872/4885HCRTR2 4844/4885CNR2 3272/4885 |
| US-20230111853-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | CRBN, STUB1, ADRM1 | HCRTR1 3772/4885HCRTR2 3728/4885CNR2 3809/4885 |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | HCRTR1 4844/4885HCRTR2 4832/4885CNR2 4255/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | HCRTR1 4844/4885HCRTR2 4832/4885CNR2 4255/4885 |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | HCRTR1 4844/4885HCRTR2 4832/4885CNR2 4255/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | HCRTR1 2369/4885HCRTR2 2110/4885CNR2 2054/4885 |
| US-11358956-B2 | Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR27, GCGR | HCRTR1 101/4885HCRTR2 29/4885CNR2 10/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HCRTR1 3716/4885HCRTR2 1754/4885CNR2 3614/4885 |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR3, GPR39 | HCRTR1 105/4885HCRTR2 27/4885CNR2 40/4885 |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | HCRTR1 39/4885HCRTR2 15/4885CNR2 8/4885 |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | HCRTR1 4844/4885HCRTR2 4832/4885CNR2 4255/4885 |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | HCRTR1 3953/4885HCRTR2 4341/4885CNR2 4875/4885 |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP5K1B, PIP4K2B | HCRTR1 4743/4885HCRTR2 4587/4885CNR2 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.